中国心血管健康研究院与安进启动战略合作

Core Viewpoint - The strategic collaboration between the China Cardiovascular Health Research Institute and Amgen aims to enhance public awareness regarding low-density lipoprotein cholesterol (LDL-C) control, facilitating early screening, intervention, and management of cardiovascular diseases, thereby supporting the high-quality development of cardiovascular health in China [1] Group 1: Cardiovascular Disease Context - Cardiovascular disease remains the leading cause of death among urban and rural residents in China, with the incidence and mortality rates of atherosclerotic cardiovascular disease (ASCVD) showing an upward trend [1] - Dyslipidemia, characterized by elevated "bad cholesterol," is a significant risk factor for ASCVD, as the accumulation of LDL-C in blood vessel endothelium can lead to atherosclerotic plaques, resulting in vascular hardening, narrowing, and potential thrombosis, which can cause acute myocardial infarction and ischemic stroke [1] Group 2: Collaboration Goals - The partnership between the China Cardiovascular Health Research Institute and Amgen aims to establish a medical ecosystem centered on "prediction and prevention," benefiting a larger patient population [1]